CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH The FDA granted selinexor (Xpovio, Karyopharm Therapeutics), a nuclear transport inhibitor, accelerated approval for this indication based on the response rate seen in the SADAL trial, a phase 2, single-arm, open-label study of patients with DLBCL who had previously received two to five systemic regimens.
Peer-influenced content. Sources you trust. No registration required. This is HCN.
